Lineage Cell Therapeutics, Inc. (LCTX)

NYSEAMERICAN: LCTX · Real-Time Price · USD

1.110

-0.050 (-4.31%)

Aug 28, 2026, 4:00 PM EDT - Market closed

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	281	405	111	191	199	413
Market Cap Growth	0.76%	265.38%	-41.93%	-4.09%	-51.84%	56.44%
Enterprise Value	232	366	79	151	134	349
Last Close Price	1.11	1.67	0.50	1.09	1.17	2.45

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	45.62	45.62	45.62	45.62	45.62
PS Ratio	21.46	27.80	11.66	21.32	13.53	95.13
PB Ratio	4.61	9.34	1.44	3.08	2.77	4.54
P/TBV Ratio	15.14	185.89	5.23	30.84	12.45	11.89
P/FCF Ratio	-	-	-	-	307.85	-
P/OCF Ratio	-	-	-	-	187.79	-

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	17.75	25.12	8.36	16.88	9.11	80.50
EV/FCF Ratio	-	-	-	-	207.31	-

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.04	0.06	0.03	0.05	0.05	0.03
Debt / FCF Ratio	-	-	-	-	6.03	-
Net Debt / Equity Ratio	-0.81	-1.23	-0.59	-0.52	-0.75	-0.61
Net Debt / EBITDA Ratio	1.86	2.53	2.17	1.59	2.48	1.15
Net Debt / FCF Ratio	1.99	2.75	1.91	1.11	-83.56	2.32
Asset Turnover	0.13	0.13	0.09	0.08	0.10	0.03
Quick Ratio	6.46	5.05	3.47	2.02	3.07	2.32
Current Ratio	6.61	5.20	3.65	2.14	3.16	2.37
Return on Equity (ROE)	-60.06%	-105.30%	-26.73%	-32.07%	-32.37%	-46.52%
Return on Assets (ROA)	-17.04%	-12.06%	-12.53%	-11.80%	-9.44%	-21.77%
Return on Capital Employed (ROCE)	-27.30%	-21.50%	-21.60%	-25.50%	-21.50%	-38.60%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	-11.49%	-15.70%	-16.80%	-11.27%	-13.21%	-10.42%
FCF Yield	-8.69%	-4.80%	-21.36%	-15.33%	0.33%	-5.79%
Buyback Yield / Dilution	-8.73%	-14.95%	-15.94%	-1.69%	-3.22%	-9.64%

SEC Filings: 10-K · 10-Q